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Abstract
Approximately 90% of the elderly population in the western countries has at 
least a mild to moderate vitamin D hypovitaminosis. Besides the well-known func-
tion of vitamin D in calcium homeostasis, it has been recently found that several 
enzymes and receptors involved in its homeostasis are expressed in the nervous 
system and brain suggesting also an important role in the brain homeostasis. 
Interestingly, epidemiological and clinical studies found reduced vitamin D level 
associated with an increased risk of several neurodegenerative disorders. In this 
chapter, we focus on a potential link between vitamin D and Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, prion disease, and motor neuron disease. 
Epidemiological studies were summarized, an overview of the known potential 
underlying pathomolecular mechanisms are given, and results from clinical stud-
ies dealing with vitamin D supplementation were presented. As an outlook, recent 
literature suggesting an impact of vitamin D on autism spectrum disease, depres-
sion, and schizophrenia are briefly discussed. In conclusion, the identification of an 
abundant vitamin D metabolism in the brain and the tight link between the increas-
ing number of several neurological and mental disorders emphasize the need of 
further research making a clear recommendation of the intake and supplementation 
of vitamin D in a growing elderly population.
Keywords: vitamin D hypovitaminosis, Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, prion disease, neuropsychiatric diseases
1.  Introduction: relationship between vitamin D and neurodegenerative 
diseases
The secosteroid vitamin D3 was identified in the year 1928 by Adolf Windaus 
and colleagues. Its synthesis starts in the skin based on 7-dehydrocholesterol 
through extraneous cause of ultraviolet B radiation in a spectrum of 290–315 nm 
wavelengths. Via the vitamin D-binding protein, it is transported in the blood to the 
liver where the 25-hydroxylase CYP2R1 hydroxylates vitamin D3 to 25-hydroxyvi-
tamin D3 (25(OH)D3). Because of its serum half-life of weeks, this 25-hydroxyl-
ated form of vitamin D3 is clinically measured as an indicator for the patients’ 
vitamin D3 level [1, 2]. The active form of vitamin D3, 1,25-dihydroxyvitamin D3 
(1α,25(OH)2D3) or calcitriol, is synthesized in the kidney by the 1α-hydroxylase 
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CYP27B1. To a limited extent, vitamin D3 can also be taken up with diet as well as 
vitamin D2 (ergo-calciferol), which is largely found in food.
Calcitriol can perform its genomic actions via vitamin D receptor (VDR) bind-
ing. Hence this undergoes a conformational change and forms a complex with the 
retinoid X receptor (RXR) which interacts with the vitamin D response element 
(VDRE) to regulate the expression of numerous genes. Because of this ability of 
transcriptional modulation, vitamin D has influence on various cellular processes, 
for example, the mitochondrial function by maintaining the mitochondrial respira-
tory chain activity [3]. Dysfunctional mitochondria will normally be removed by 
autophagy, a process that is also promoted by vitamin D [4]. Damaged mitochon-
dria could induce inflammation. Vitamin D is able to downregulate the expression 
of pro-inflammatory cytokines such as the tumor necrosis factor-α (TNF-α) or 
interleukin-6 (IL-6), thereby reducing inflammation [5]. Additionally to these 
cellular processes, vitamin D antagonizes oxidative stress by enhancing the expres-
sion of antioxidants and thereby reduces levels of reactive oxygen species (ROS) 
[6]. Furthermore the expression of the voltage sensitive L-type Ca2+ channels is 
suppressed by vitamin D to regulate intraneural calcium [7, 8]. Vitamin D also plays 
a role in DNA-related cellular processes, for example, epigenetic changes. These 
are influenced on the one hand by oxidative stress which is regulated by vitamin 
D, as described before, and on the other hand by histone methylation which is 
also modulated by vitamin D due to its influence on the transcription of key DNA 
demethylases [9, 10].
Based on the fact that up to 90% of the elderly population is suffering from 
a vitamin D hypovitaminosis because of a homebound lifestyle and the reduced 
ability of their skin to generate vitamin D3, the idea arose to analyze the impact of a 
vitamin D deficit on the abovementioned cellular processes which are all involved 
in ageing [11]. Moreover, ageing is a risk factor for neurodegenerative disorders. 
Michael J. Berridge published a very detailed article 2 years ago reviewing the 
influence of vitamin D deficiency on ageing and age-related diseases. He figured 
out that hypovitaminosis D promotes those ageing-related processes, for example, 
due to a decline of mitochondrial respiration or the electron transport chain. This 
dysfunction leads to an increase in oxidative stress and inflammation, main drivers 
of ageing. Furthermore, he describes elevated Ca2+ levels in neurons during ageing 
which are accompanied by a decline in cognition. This observation can be restored 
by vitamin D due to its ability to reduce the levels of Ca2+. Additionally, telomere 
shortening, a DNA-related process that is involved in ageing, is reported to be 
decreased by vitamin D [12]. Those upregulated ageing processes under vitamin 
D-deficient conditions in the elderly population could further lead to age-related 
disorders like dementia or declines in cognition.
A relationship between vitamin D and age-related cognitive disorders was 
further strengthened by the findings that vitamin D and its metabolites are able 
to cross the blood-brain barrier. Early research reported the presence of vitamin 
D metabolism intermediates and products in human cerebrospinal fluid [13]. 
Furthermore, due to the presence of the metabolizing hydroxylases in the brain, the 
active form of this hormone-like secosteroid can be synthesized in the human brain. 
The additive existence of the VDR in neuronal and glial cells suggests that vitamin 
D might influence functioning of the central nervous system (CNS) [14]. As 
mentioned earlier, the VDR-mediated nuclear functions of 1,25(OH)2D3 influence 
cellular processes, for example, immune modulation and cell growth or differentia-
tion. Those biological systems have also an impact on maintaining the function 
of the brain. Annweiler et al. reported increased risks of cognitive disorders for 
patients with 25(OH)D3 serum concentrations lower than 10 ng/ml [15]. Vitamin 
D influences the structure of the brain, like changes in volume and vasculature as 
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well as its metabolism [16]. Furthermore, in vivo studies using offspring of vitamin 
D-deficient rats could show that vitamin D plays an important role in the devel-
oping brain [17]. Eyles et al. give a detailed overview in their review over all the 
different animal studies that have been made in this context. One exemplary finding 
is that rats with a vitamin D deficiency during their development have impairments 
in their adult behavior [18].
In a retrospective study from 2007, Przybelski and colleagues reported that 
serum 25(OH)D3 can be positively associated with increased cognitive function 
[19]. Consistent finding results from a prospective cohort study in older adults that 
showed a vitamin D hypovitaminosis (levels <30 ng/mL) in 68% of the participants 
and moreover that these ones have lower baseline cognitive function and increased 
decline over the 4 years of follow-up [20]. In the same year, another prospective 
study including 1185 women also pointed out an association of higher plasma 
25(OH)D3 levels and better cognitive performance [21]. A meta-analysis showed 
that participants with insufficient vitamin D levels have a 2.4-fold increased risk 
of cognitive impairments than those with sufficient levels [22]. In line with this, 
further systematic reviews and meta-analysis support an association between 
hypovitaminosis D and declined cognitive functions [23, 24]. Additionally, some 
longitudinal studies suggest a link between low serum 25(OH)D3 levels and cog-
nitive performance. Toffanello et al. reported decreasing scores at Mini-Mental 
State Examination (MMSE) in participants having serum 25(OH)D3 levels below 
75 nmol/L in their 4.4-year follow-up study including 1927 elderly subjects [25]. 
One year later, Miller et al. published a vitamin D-associated accelerated decline in 
cognitive performance in their study of a multiethnic cohort of older adults [26]. 
In line with these data, a more recent clinical study in the elderly US population 
(3325 participants) reported that low serum levels of vitamin D3 are linked to an 
enhanced risk of cognitive impairment [27].
Due to the suggested role of vitamin D in brain function, several studies examin-
ing the effect of dietary supplemented vitamin D exist. Animal studies and epide-
miological studies generate biological evidences for a relationship between vitamin 
D levels and brain health. Latimer et al. could show that a 6-month supplementa-
tion of vitamin D improves cognitive function in a rat model of aging [28]. One 
study from Annweiler and colleagues in the year 2010, including 5596 women with 
a mean age of 80.5 years, concluded that higher weekly dietary vitamin D intake is 
associated with better cognitive performance in older adults [29]. In line with this, 
a current cross-sectional and longitudinal study describes a significant association 
between serum vitamin D levels below 30 nmol/L and reduced general cognitive 
performance [30].
Unlike those animal and epidemiological findings, clinical studies using ran-
domized controls examining the role of vitamin D in individuals without any form 
of dementia show heterogeneous data [31–34]. In general, it should not be disre-
garded that differences in clinical intervention studies might be because included 
participants who already had sufficient vitamin D levels at baseline could mask 
the benefit of supplementation on cognitive function. To prevent this, it would be 
beneficial including exclusively participants affected by a hypovitaminosis D at the 
baseline measurement. These inconclusive data also support the idea of individually 
adjusted supplementation protocols for each patient. Furthermore, methodological 
differences between the studies, for example, duration, form, and dose of vitamin 
D supplementation, have to be considered. A current study from Pettersen et al. 
[35] considered these abovementioned methodological pitfalls by administering 
4000 IU/day of vitamin D3 for 18 weeks to healthy adults and by baseline as well as 
endpoint measurements of serum 25(OH)D3 levels. Furthermore, they were able 
to distinguish between the two cognitive domains, verbal and visual memory, with 
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several cognitive tests. High doses of vitamin D enhanced visual memory, while 
low doses (400 IU/day) improved verbal memory. As summarized by the authors, 
there seems to be a small positive effect of vitamin D3 supplementation on executive 
functioning, despite the outlined limitations (modest sample size with wide range 
of ages, no true placebo group) [35]. Recently, Aspell et al. give a well elaborated 
overview over a possible supporting role of vitamin D in cognitive function in age 
[36]. In the following chapter, we will present the results of current available studies 
examining the impact of vitamin D supplementation on brain-related disorders for 
each neurodegenerative disease itself. Up to this date, also the nutrition research 
field examines the influence of dietary components on brain health. In a recent 
review from Moore et al., the authors describe a potential protective role for vitamin 
D among others [37].
2. Alzheimer’s disease
Alzheimer’s disease (AD) can be described as a multifactorial, metabolic disease 
as this disease is characterized by impairments in multiple cellular processes. For 
example, AD pathology includes alterations in the sequential proteolytic processing 
of the amyloid precursor protein (APP) which results in the formation of neuro-
toxic Aβ plaques, in the phosphorylation of the microtubule-associated protein Tau, 
in lipid and energy metabolism, and in inflammation. Among others, AD patho-
genesis is influenced by lipophilic vitamins [38].
Epidemiological studies indicate a relationship between vitamin D deficiency 
and AD. A systematic review and meta-analysis concluded that patients affected by 
AD have lower levels of serum 25(OH)D3 than healthy controls [39]. Furthermore 
the level of vitamin D is shown to be significantly reduced in the cerebrospinal fluid 
of AD patients [40]. Another meta-analysis from Shen and colleagues shows that 
vitamin D hypovitaminosis (25(OH)D3 level < 50 nmol/L) is associated with a 21% 
increased risk of AD [41]. Different results were obtained by a study, measuring 
serum level of 25(OH)D3 via radioimmunoassay in patients with MCI or diag-
nosed dementia compared to healthy controls. Analysis of the cognitive perfor-
mance showed significant differences between these groups. Vitamin D levels of 
65.2 ± 17.9 nmol/L for controls, 61.4 ± 18.8 nmol/L for MCI, and 65.0 ± 20.3 nmol/L 
for AD were reported in this study; however the differences in vitamin D con-
centrations between these groups were not statistically significant. Interestingly, 
the authors show that approximately 12% of the MCI and AD patients used some 
kind of vitamin D supplementation, whereas only 5% of healthy controls did so. 
Furthermore, 80% of the MCI patients, 50% of the AD patients, and 62% of the 
control individuals regularly used nutritional supplements, which could have influ-
enced the results as discussed by the authors. In conclusion, the authors comment 
that their “findings cannot exclude the possibility that targeted vitamin supplemen-
tation can act as a modifying measure, although it is less likely that vitamin intake 
can prevent dementia onset” [42].
Several longitudinal studies provide homogeneous results indicating that a 
deficiency in serum 25(OH)D3 is linked to a greater risk and incidence of dementia 
and AD [43–47]. A current prospective study analyzed 25(OH)D3 level, cognitive 
decline, and incidence of dementia in 916 patients for 12 years and reported a more 
pronounced cognitive decline and a threefold increased risk of AD in individuals 
with hypovitaminosis D [48].
In line, a study from 2018 analyzing the serum vitamin D level in AD patients 
described decreased levels in various stages of AD. Additionally, the authors 
indicate 25(OH)D3 as significant predictor for severe AD and argue for vitamin D 
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supplementation in AD patients [49]. Moreover, Wang et al. recently reported a 
delayed onset of psychotic symptoms when vitamin D was used in AD patients and 
suggest variations in vitamin D-influenced genes as biomarkers for those individu-
als who can have a benefit from supplementation [50].
These studies consistently indicate a link between insufficient dietary intake of 
vitamin D and cognitive diseases like AD. However, these studies did not address 
the question whether vitamin D deficiency is a cause and thus risk factor for AD or 
a consequence of this neurodegenerative disease mediated by accompanying dietary 
and behavioral changes. Some more evidence of a causal relationship between 
hypovitaminosis D and AD was achieved by Mendelian randomization (MR) 
studies that use genetic associations on inherited alleles unaffected by confound-
ing factors or disease progression. It was reported that two polymorphisms in the 
VDR gene are associated with AD risk in patients younger than 76 years [51]. A 
subsequent meta-analysis including six AD studies also revealed this relationship 
[52], as well as an earlier study using genotyping of 213 participants [53]. Wang 
et al. also provide this genetic evidence and could further generate functional data 
indicating a link between the VDR and the genetic AD risk [54]. Furthermore, the 
study of Mokry and colleagues supports genetically decreased vitamin D levels 
as causal risk of AD, by analyzing the effect of single-nucleotide polymorphisms 
(SNPs) involved in vitamin D metabolism on 25(OH)D3 levels and the risk of AD in 
more than 56,000 participants [55]. A recently published MR study from Larsson 
and colleagues including 17,008 AD cases and 37,154 controls reported an inverse 
association between 7 SNPs related to elevated vitamin D3 levels with AD, in which 
2 of them were significant [56]. A study creating a vitamin D synthesis risk score 
analyzing more than 1000 Swedish men in a follow-up of 18 years is controversially 
discussed as this study revealed no link between baseline vitamin D status and the 
long-term risk of dementia [57].
Concerning clinical studies, randomized placebo-controlled trials analyzing the 
effect of vitamin D supplementation on AD risk and progression are still missing. 
However, recently nonrandomized studies showed positive findings about that 
relationship. A current study reported improvements in the cognitive status of MCI 
patients (n = 16) in an 18-month follow-up after 6 months of vitamin D supple-
mentation. Additionally, vitamin D supplementation protected lymphocytes from 
oxidative stress [58].
In contrast to the missing clinical trials, several animal and cell culture studies 
underline a causal relationship between vitamin D and AD. One study described an 
increased neurogenesis and enhanced cognition after feeding a transgenic mouse 
model of AD (5xFAD mouse model) with a daily dose of 500 IU/kg vitamin D 
for 5 months [59]. Additionally, animal and cell culture studies allow analyzing 
combination therapies, for example, a supplementation of both vitamin D and 
resveratrol. This resulted in an improvement of cognitive function and reduced 
levels of Aβ42 in the hippocampus along with decreased tau phosphorylation in the 
parietal cortex of a mouse model with AD-related memory impairment [60]. In 
line, a novel study from 2019 reported an improvement of the AD-related pathol-
ogy in 5xFAD mice after intravenous injection of vitamin D-binding protein which 
was loaded on a biocompatible polymer (PLGA) [61]. Especially cell culture and 
animal-based studies are indispensable for clarifying the molecular mechanisms 
of vitamin D action in neurodegenerative diseases. They revealed that vitamin 
D exerts its protective effects via VDR-related, genomic, as well as non-genomic 
actions directed to processes like Aβ metabolism, neurogenesis, immune modula-
tion, and neuronal calcium homeostasis. A study from Landel et al. examined the 
transcriptome of 5xFAD mice after 5 months of vitamin D3 supplementation and 
reported a large number of differentially expressed genes. The authors suggest an 
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interaction of vitamin D with estrogen and insulin signaling to regulate the identi-
fied pathways [62]. Consistently, we could show that a deficit of vitamin D causes a 
dysregulation of numerous genes that are involved in multiple cellular processes like 
neurogenesis, inflammation, mitochondrial function, oxidative stress, signal trans-
duction, and APP homeostasis in brains of hypovitaminosis D mice [63]. In respect 
to the impaired APP homeostasis, several studies using primary cortical neurons or 
human neuroblastoma cell lines were able to show beneficial effects of vitamin D 
and its analogues on anabolism and catabolism of the neurotoxic Aβ peptide  
[64, 65]. In line with these findings, a vitamin D3-enriched diet leads to an increased 
Aβ clearance in mouse models of AD [66–68]. Consistent with the results of animal 
studies, Hooshmand et al. could demonstrate an association of increased plasma 
25(OH)D3 levels with higher concentrations of CSF Aβ1-42 in 75 patients, reflect-
ing a decreased Aβ1-42 aggregation in human brain parenchyma [69]. In contrast, a 
recent cross-sectional study failed to find significant associations between plasma 
vitamin D levels at baseline and Aβ load in different brain regions. But the authors 
themselves argue that those findings could be explained by an improper timing of 
measurements or rather no analysis over time or by a hypovitaminosis D-related 
cognitive decline independent of APP homeostasis [70]. The potential neuroprotec-
tive role of vitamin D3 is based on findings that it regulates the transcription of the 
neurotrophin nerve growth factor, glial-derived nerve factor, and neurotrophin 3 
which are important for neuronal survival [71–73]. Furthermore, the expression 
of the neuroprotective cytokine IL-34 was shown to be increased in dose- and 
time-dependent manner by calcitriol in neuroblastoma cells [74]. In respect to a 
relationship between vitamin D and neuronal calcium levels, a review describes a 
reduced autophagy due to impairments in calcium signaling as a consequence of 
hypovitaminosis D [6].
3. Parkinson’s disease
As one of the most common neurodegenerative diseases, Parkinson’s disease 
(PD) is characterized by the loss of dopamine-producing neurons in the substantia 
nigra pars compacta and typical Lewy bodies, aggregates of α-synuclein, provoking 
oxidative stress and further cell death, leading to impairments in cognition and 
behavior and to dysautonomia [75].
A number of epidemiological studies were able to indicate an association of 
vitamin D and PD. Several evidences exist that hypovitaminosis D is more frequent 
in PD patients [76, 77], and a cohort study with a 29-year follow-up reported a 
decreased risk of PD in individuals with higher vitamin D serum levels [78]. These 
findings are supported by the outcomes of recent studies describing significantly 
reduced levels of serum 25(OH)D3, daily vitamin D intake, and sunlight exposure 
in PD patients [79]. Besides significantly decreased serum 25(OH)D3 levels, also an 
association of vitamin D at baseline and disease motor severity after 36 months was 
observed in a recently published prospective observational study [80]. A clinical 
study found an inverse relationship between serum vitamin D concentrations and 
disease severity as well as an influence on balance function in PD patients [81]. A 
current study reported that vitamin D status of PD patients has no influence on 
nocturnal changes in blood pressure, a marker of cardiac autonomic dysfunction 
as non-motor symptom in PD [82]. However, the tight link between serum vitamin 
D concentrations and risk as well as severity of PD is also underlined by a recent 
systematic review and meta-analysis of Luo et al. [83].
PD is not only caused by environmental factors, for example, the vitamin D 
status, but also by genetic components. The first monogenetic mutation, which was 
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found to be associated with early onset familial PD, is located in the SNCA gene that 
encodes the α-synuclein protein [84]. A recent study was able to show an altered 
expression of Snca in brains of vitamin D-deficient mice, underlining a causal rela-
tionship between hypovitaminosis and PD [63]. Consistent with several previous 
publications, this is also supported by two recent studies analyzing SNPs in VDR 
and the vitamin D-binding protein. Besides the functional VDR polymorphism, 
FokI was reported to be associated with cognitive decline in PD and ApaI with the 
risk of PD, while vitamin D-binding protein gene was suggested as a risk factor 
for PD [85, 86]. In line with this, a double-blind, placebo-controlled intervention 
study from Suzuki and colleagues, including 114 PD patients, was able to reveal 
that supplementation of 1200 IU vitamin D3/day prevents disease progression in a 
VDR FokI genotype-dependent manner [87]. Moreover, high-dose supplementation 
of vitamin D (10,000 IU/day) resulted in significant improved balance measured 
via sensory organization test in PD patients with an age of 52–66 but not in older 
individuals [88].
To elucidate the underlying molecular mechanisms by which vitamin D exerts 
its potential beneficial role, animal and cell culture experiments were performed. 
Vitamin D3 seems to have a positive influence on synthesis and storage of dopamine 
in CNS by protecting against dopaminergic toxins such as 6-hydroxydopamine 
or hydrogen peroxide in rats [89]. This neuroprotective effect could be due to its 
ability to elevate the expression of the glial cell line-derived neurotrophic factor 
(GDNF) that influences the dopaminergic nigrostriatal system [90] and due to its 
antioxidative properties described before. Furthermore vitamin D3 administration 
was shown to prevent zinc-induced oxidative stress in substantia nigra of rat brain 
[91]. Oxidative stress and elevated intracellular-free calcium promote the aggrega-
tion of α-synuclein synergistically, and a recent study could show that the vitamin 
D3 analogue calcipotriol is able to induce the expression of calbindin-D28k, thereby 
inhibiting the calcium-mediated aggregation of α-synuclein in human neuroblas-
toma cells [92].
4. Multiple sclerosis
Multiple sclerosis (MS) is a multifactorial, chronic disease of the CNS character-
ized by demyelination, inflammation, and neurodegeneration.
Epidemiological studies indicate that genetic and environmental factors interact 
and influence the risk of MS, for example, several SNPs or environmental exposures 
like an infection with Epstein-Barr virus (EBV), vitamin D status, sunlight expo-
sure, or smoking. There is a high prevalence for MS in areas with low sun/ultraviolet 
sun exposure [93, 94], and this could be explained by vitamin D [95]. A study from 
Lucas and colleagues revealed that vitamin D and sun exposure are independent 
risk factors of CNS demyelination [96]. For an overview over environmental factors 
and MS, we suggest an article from Ebers GC [97]. Genetic predispositions which 
are associated with MS are found in genes of the immune system. The strongest 
correlation was found for genes of the major histocompatibility complex (MHC), 
especially the HLA genotype HLA-DRB1 [98]. Findings from Ramagopalan and 
colleagues suggest a direct functional link between known environmental risk fac-
tors, for example, vitamin D, and established genetic predispositions. The authors 
described the localization of a vitamin D response element on the promotor region 
of HLA-DRB1 and underlined its functional role by the finding that treatment with 
calcitriol results in an increased expression [99]. Later on this research group could 
show that mutations in the CYP27B1 gene, involved in vitamin D3 metabolism, 
are causative associated with the risk of MS [100]. Moreover, genetic variations 
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in the CYP24A1 gene, involved in catabolism of vitamin D, were found to play a 
pathogenic role in MS [101]. For detailed information about the results of several 
genome-wide association studies analyzing the genetic risk of developing MS, we 
recommend a recent publication from Baranzini and Oksenberg [102].
Clinical studies indicate that vitamin D influences MS development and disease 
activity including the risk of relapse, gray matter volume loss, and clinical course 
of MS. A prospective study from Munger et al. included participants from the US 
military personnel and reported a significantly decreased risk of MS with elevated 
levels of 25(OH)D3 [103]. Furthermore, a cross-sectional study described a link of 
serum 25(OH)D3 levels with both relapse rate and disability in MS patients [104]. In 
line with this, an association of reduced serum 25(OH)D3 levels with a higher risk of 
relapse in MS was reported in a prospective longitudinal study including 73 indi-
viduals with relapsing-remitting MS [105]. Consistent findings are obtained from 
a retrospective study describing an association of a 10 ng/ml increase in 25(OH)D3 
level with a 34% reduced relapse rate in pediatric-onset MS [106] and from a pro-
spective study reporting a 25(OH)D3 elevation of 10 nmol/L to be associated with a 
12% decreased risk of relapse in a cohort including 145 participants [107]. A 5-year 
longitudinal study from Mowry and colleagues using magnetic resonance imaging 
(MRI) as marker of disease activity provided evidences for a lower risk of develop-
ing new T2 lesions and gadolinium-enhancing lesions as well as reduced subsequent 
disability attended by an 10 ng/ml increase in 25(OH)D3 level [108].
As mentioned before in the context of AD, these clinical studies are not able to 
rule out the possibility of reverse causality. In this context MR studies are of great 
interest analyzing this potential causal relationship of vitamin D and MS risk. 
Mokry et al. identified four 25(OH)D3 level-associated SNPs in a large genome-wide 
association study for vitamin D, called SUNLIGHT, and performed an MR study to 
examine the influence of genetically reduced vitamin D3 levels on the odds of MS 
in a large genetic association study for MS. This leads to the finding that genetically 
reduced vitamin D3 levels are strongly linked to an elevated MS risk [109]. This 
thesis is furthermore supported by another novel MR study that described causal 
effects of decreased vitamin D3 levels on pediatric-onset MS [110]. A very recent 
study from Graves et al. provides evidence for a causal link between 25(OH)D3 and 
MS relapses in children. The authors indicate that a vitamin D genetic risk score 
(vitDGRS) can support the identification of patients at greater relapse risk [111].
The protective role of vitamin D could be exerted on the molecular level mainly 
due to its several potential immunomodulatory effects. These are summarized in 
a review from Smolders and colleagues. The authors pointed out that vitamin D 
causes a shift to an anti-inflammatory immune response and increased regulatory T 
cells as well as reduced pro-inflammatory helper cells like Th1 and Th17 selectively 
[112]. In line with this, a study from Munger et al. reported an overlap of genes 
associated with vitamin D3 and those associated with processes of immune regula-
tion. Furthermore they suggest the sphingosine-1-phosphate receptor-dependent 
migration of lymphocytes from secondary lymphoid tissue as potential vitamin D3-
mediated mechanism [113]. Additional evidences for the MS-underlying molecular 
mechanisms arise from a recent study using the L-type calcium channel antagonist 
nimodipine, showing decreased neurodegeneration in experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS. The authors reported calcium 
channel-independent, microglia-specific effects: induction of apoptosis, reduced 
levels of NO and ROS, as well as positive effects on remyelination [114].
Based on the results of all these studies demonstrating a causal link between 
vitamin D hypovitaminosis and the risk of MS, the role of vitamin D3 supple-
mentation in MS therapy was investigated. A study from Munger et al. reported 
an approximately 41% reduced relative risk of MS due to the supplementation of 
9The Effects of Vitamin D Deficiency on Neurodegenerative Diseases
DOI: http://dx.doi.org/10.5772/intechopen.89160
400 IU vitamin D/day in two large cohorts of women [115]. Several following stud-
ies also describe beneficial effects of vitamin D3 supplementation on gadolinium-
enhancing lesions, relapses, and T-cell proliferation without unrequested calcemic 
side effects [116–118]. Inconsistent with these results, another study revealed no 
positive effect of high-dose vitamin D3 supplementation (20,000 IU/week) on 
course and activity of the disease, for example, the relapse risk. A possible explana-
tion for this finding could be individuals with high vitamin D3 levels in the placebo 
group. Furthermore the authors could not preclude that the used vitamin D dose 
was too low or that the sample size was too small [119]. In this context it should be 
mentioned that the individual vitamin D metabolism, which could be influenced 
by genetically mutations in the enzymes required for the anabolism and catabolism 
of vitamin D3 as discussed before, has to be analyzed since this would influence 
the response to identical supplemented doses of vitamin D in different individu-
als [120]. Subsequent studies were able to show a reduction in relapse rate after 
supplementation of vitamin D3 [121] and an improved cognitive performance [122]. 
Oral supplementation of 20,000 IU vitamin D3/week in a 96-week randomized 
double-blind placebo-controlled study in 68 MS patients results in reduced levels 
of anti-EBV nuclear antigen 1 (EBNA1) protein and fragment antibody [123]. A 
previous study could show a remarkable overlap of EBNA2 with VDR binding sites 
and thereby demonstrates a genetic argument for an interaction between genetic 
and environmental risk factors of MS [124]. A current study reports that long-term 
supplementation for several months with high doses of cholecalciferol results in 
a significantly promoted aggravation of clinical and histological EAE, but simul-
taneously they find a direct, anti-inflammatory, beneficial effect of vitamin D on 
lymphocytes of human and murine origin [125].
5. Prion diseases
Prion diseases are a group of neurodegenerative disorders whose pathology is 
caused by the conversion of the cellular prion protein (PrPC) into a misfolded form 
of the protein, called prion or “scrapie prion protein” (PrPSc), a proteinaceous, 
insoluble, infectious particle which is resistant to proteases and seems to act as tem-
plate for exponential transformation and further accumulation of prion proteins. 
One characteristic of prion diseases is their appearance by sporadic (spontaneously 
conversion, Jakob-Creutzfeldt disease), genetic (familial mutations in the prion 
protein gene, PRNP), or acquired (accidentally transmission or infection) mecha-
nisms [126].
A study on transgenic mice was able to identify a naturally occurring polymor-
phism in the human PRNP which is very rare but seems to completely prevent prion 
disease [127]. Up to this date, no clinical trial on human prion disease was success-
ful, and most of the analyzed chemical compounds failed as potential therapeutics 
because of their toxicity. A study from Suenaga and colleagues intended to identify 
compounds that interfere with the direct PrPC-PrPSc interaction by screening 
hydrophobic vitamins. The authors reported for the first time that vitamin D2 was 
able to interact with a truncated form of human recombinant PrPC leading to a 
reduced oligomerization in vitro. The absence of such an effect mediated by vitamin 
D3 could be due to structural differences between these two vitamin D forms. This 
study suggests vitamin D2 as suitable therapeutic candidate to target PrPC in the 
brain of patients with prion disease because of its direct inhibition of PrPC oligo-
merization, its blood–brain barrier permeability, and its safety compared to other 
synthetic compounds [128]. But apart from that, more studies, especially clinical 
trials, are essential to elucidate the relationship of vitamin D and prion diseases.
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6. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects 
upper and lower motor neurons in the brain and spinal cord resulting in paralysis 
[129]. It is characterized, similar to the abovementioned vitamin D3-associated 
diseases, by oxidative stress, inflammation, mitochondrial dysfunction, and 
neurodegeneration [130].
Clinical studies result in inhomogeneous findings about a possible role of 
vitamin D on ALS. A retrospective study including 57 ALS patients reported neither 
significant differences in 25(OH)D3/D2 blood levels in comparison to 57 healthy 
individuals nor an improvement of the recorded clinical, ALS-related variables after 
oral supplementation of 100,000 IU of vitamin D3/week for 4 weeks and thereafter 
25,000 IU every 15 days compared to untreated participants. But as discussed by the 
authors, potential limitations of this study are its retrospective character and the 
sample size [131]. Two earlier studies also described an absent relationship between 
serum 25(OH)D3 levels and prognosis in ALS [132, 133]. A very recent study exam-
ined the outcome of supplementation of 50,000, 75,000, and 100,000 IU vitamin 
D3/month on motor dysfunction and clinical progression of ALS. After 6 months, 
they reported increased levels of serum 25(OH)D3 from approximately 14 ng/mL 
at starting point to approximately 40 ng/mL after supplementation of 75,000 and 
100,000 IU vitamin D3 monthly, but there were no statistically significant differ-
ences in the tested clinical ALS characteristics. As the authors mention, the sample 
size of 10–12 participants per group as well as the short duration of the follow-up 
study has to be taken into consideration [134].
In contrast to these findings, a study from Karam et al. reported vitamin D level 
less than 30 ng/mL for 81% of their patients with ALS and additionally improve-
ments in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) 
score after supplementation of 2000 IU vitamin D/day for 9 months in 20 partici-
pants [135]. In line, a subsequent study described a neuroprotective role for the 
biologically active form of vitamin D3 as well as a four-time accelerated decline 
and reduced expectation of life due to hypovitaminosis D [136]. These variable 
outcomes strengthen the need of further clinical studies with an adequate sample 
size to reach statistical power and follow-up period analyzing the effect of vitamin 
D3 on ALS. A first evidence of a genetic link between vitamin D3 and ALS arises 
from a study from Török and colleagues describing that a SNP in the VDR gene is 
associated with ALS [137]. Further suggestions of a potential role of the VDR in 
ALS derived from the finding that VDR-knockout mice have muscular and motor 
disruptions but no reduced cognitive performance [138].
In contrast to the ambiguous clinical studies, animal trials provide evidences for 
a positive effect of supplemented vitamin D3 on ALS. Studies from Gianforcaro and 
colleagues reported beneficial functions of high-dose dietary vitamin D3 supple-
mentation on the paw grip endurance and motor performance of transgenic G93A 
ALS mouse model while decreased performance of functional outcome in vitamin 
D3 deficient mice [139, 140].
In reference to the above itemized similarities in ALS characteristics with other 
neurodegenerative diseases, it is not remarkable that the molecular mechanisms of 
which vitamin D3 is suggested to have a beneficial influence on ALS are overlap-
ping. Vitamin D3 could decrease the elevated levels of TNF-α or IL-6 found in 
ALS patients [141] or influence calcium metabolism by regulating the expression 
of calcium-binding proteins, known to be impaired in ALS [142]. More detailed 
information can be found in the publications from Gianforcaro et al. and Long 
et al. [143, 144].
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7. Huntington’s disease
Up to this date, only a few studies are available examining a possible relationship 
between vitamin D3 and Huntington’s disease (HD), a neurodegenerative disorder 
characterized by impairments in cognition, motor behavior, and psychiatrics. HD 
is caused on molecular level by an expansion of an autosomal dominantly inher-
ited CAG trinucleotide repeat in the huntingtin (HTT) gene which is located on 
chromosome four in humans. This leads to the expression of a mutant huntingtin 
protein containing an abnormal long polyglutamine repeat [145]. The number of 
repeats is associated with the risk of developing HD [146]. A recent clinical review 
describes the consequences of mutant huntingtin on cellular level, including 
interferences in transcription and protein homeostasis as well as mitochondrial 
dysfunction and direct toxicity of the altered protein itself. This leads to a disrup-
tion in neuronal function and further cell death and neurodegeneration [147]. To 
our knowledge, there are no current epidemiological or clinical studies suggesting a 
relationship between vitamin D status and HD, just an explorative study from Chel 
and colleagues. They reported a high prevalence of deficient or insufficient serum 
vitamin D level (<50 nmol/L) in 28 individuals with manifest HD [148]. In line with 
this, a recent study on HD transgenic mice showed no effect on motor performance 
but a significantly prolonged lifespan after subcutaneous supplementation of 
12,000 IU vitamin D3 per kilogram weight [149]. Further evidences for an influ-
ence of vitamin D3 on HD arise from a recent publication of Seuter and colleagues 
analyzing the epigenome-wide effects of vitamin D in THP-1 human monocytes. 
They identified 165 physiologically important target genes after supplementation of 
1,25-dihydroxyvitamin D3 being one of them the HTT gene [150].
8. Neuropsychiatric diseases
Beside neurodegenerative disorders also neuropsychiatric diseases affect the 
nervous system, and therefore we would like to give a brief summary of recent 
studies analyzing a possible influence of vitamin D on autism spectrum disorders 
(ASD), depression, and schizophrenia. Epidemiological studies demonstrated 
an elevated prevalence for ASD in children born at higher latitudes [151] and in 
offspring of highly pigmented women [152] as well as lower vitamin D levels of 
children with autism [153]. Furthermore maternal, gestational hypovitaminosis D 
is associated with a higher ASD risk [154, 155]. Recent findings of strong associa-
tions of ASD with polymorphisms in the VDR or other genes involved in vitamin D3 
metabolism [156, 157] hypothesize vitamin D3 as environmental and genetic factor 
influencing ASD [158]. On the molecular level, cellular processes like oxidative 
stress or neuroinflammation were shown to play a role in ASD [159], and they could 
present a potential contact point for vitamin D3. In line with the abovementioned 
link between ASD and vitamin D, a vitamin D-deficient rat model revealed broad 
behavioral similarities between vitamin D-deficient models and ASD-associated 
behavior [160]. Treatment of an ASD rat model with high-dose vitamin D revealed 
significant protective effects [161]. In contrast to supplementation in animal trials, 
the first randomized controlled clinical study analyzing the daily supplementation 
of 300 IU vitamin D3/kg for 4 months on 109 children with ASD, resulting in sig-
nificant improvement of autism symptoms, was retracted 1 month ago [162]. This 
lets us conclude that vitamin D3 can be suggested as possible preventive treatment 
for the prevention of ASD, but more studies supplementing pregnant women and 
their children with adequate levels of vitamin D3 have to be performed.
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A potential link between vitamin D3 and depression is subject of current 
research, and for more detailed information about the potential role of vitamin D 
on major depressive disorder, we recommend a review from Casseb et al. [163]. 
A meta-analysis from Parker and colleagues concluded that there are increasing 
evidences for an influence of vitamin D on depression [164], and in line with this, 
another review also postulated hypovitaminosis D as risk factor for late-life depres-
sion [165]. Consistently, a very recent meta-analysis reported a negative association 
of serum 25(OH)D3 levels with the risk of depression [166].
A following cross-sectional study including 100 women in reproductive age also 
shows that the depression score inverse correlated with the vitamin D serum level 
[167]. Contradictorily, a supplementation with 1200 IU vitamin D for 12 months 
failed to have an influence on the prevention of depression in a very recent, 
randomized clinical trial including 155 participants having clinically relevant 
depressive symptoms [168]. Furthermore, a recent MR study from Libuda and 
colleagues indicates no causal relationship between both depressive symptoms and 
broad depression and vitamin D levels due to a missing association of six vitamin 
D-related SNPs with depression [169]. In summary, the current research investigat-
ing the role of vitamin D3 in depression is much less clear than other neurological 
disorders.
In respect to the chronic mental illness schizophrenia, it could be shown that 
hypovitaminosis D is common in patients [170]. This fits to the environmental 
risk factors that have been described for schizophrenia, like season of birth [171] 
and latitude [172]. Also a link between neonatal vitamin D levels and the schizo-
phrenia risk was reported [173]. A recent randomized, placebo-controlled study 
from Krivoy and colleagues examined psychosis severity, mood, cognition, and 
metabolic profile in 47 schizophrenia patients during an 8-week supplementation 
of 14,000 IU vitamin D/week. The authors described no significant effects on 
psychosis, mood, or metabolic status, but a trend to an improved cognitive function 
accompanied by significant elevated vitamin D levels in the supplemented group. A 
possible explanation for these findings, given by the authors, could be that a medi-
cal score that measures the symptom severity in schizophrenia patients decreased 
during the study in the placebo as well as in the treated group and could thereby veil 
the influence of supplemented vitamin D [174]. An actual study reported beneficial 
effects of supplementation of vitamin D3 in combination with probiotics in schizo-
phrenia patients [175]. Addressing the underlying molecular mechanism, vitamin 
D could perform its suggested beneficial actions via modulation of immune system 
and inflammation processes since it was reported that patients with chronic schizo-
phrenia have significantly elevated levels of TNF-α and IL-6 [176]. Furthermore, it 
could be shown that the expression of genes involved in the metabolism of vitamin 
D3 (VDR, CYP27B1, CYP24A1) is significantly elevated in peripheral blood of 
schizophrenic patients [177], indicating a potential causal relationship between 
vitamin D3 and schizophrenia, which should be the aim of future research.
9. Conclusion
In summary, in the current literature, several lines of evidence suggest a tight 
link between vitamin D3 and neurodegenerative diseases (see Table 1). Besides 
epidemiological studies, vitamin D deficiency influences several pathways associ-
ated with neurodegenerative diseases, which also indicates a causal link of hypovi-
taminosis D and AD, MS, and PD. As a consequence, vitamin D hypovitaminosis is 
broadly assumed to be a risk factor for these diseases. In addition, recent literature 
underlines a potential link between prion diseases, ALS, HD, and neuropsychiatric 
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Alzheimer’s 
disease
Parkinson’s disease Multiple sclerosis Prion disease Amyotrophic 
lateral sclerosis
Huntington’s disease
Epidemiological and 
clinical studies
Vit. D levels ↓ 
[39, 40]
Risk factor
[41, 43–48]
Causal link
[51–56]
Vit. D levels ↓ 
[76–79]
Severity of PD 
[80–81, 83]
Genetic link
[85–86]
Risk factor
[96, 103]
Genetic predisposition 
[99–101]
Causal link
[109–111]
/ Non-consistent 
findings
[132, 133, 136]
Evidence of genetic 
link
[137]
Vit. D levels ↓ [148]
Animal and cell 
culture studies
Causal link
[63]
Transcription
[62]
Causal relationship 
[63]
Regulatory
T cells ↑
[112]
Vit. D2 as suitable 
therapeutic candidate
[128]
Potential role of the 
VDR
[138]
Benefits after 
supplementation
[139, 140]
Vit. D supplementation ↓ 
prolonged lifespan
[149]
Epigenomic action on HTT 
gene
[150]
Molecular 
mechanisms
APP homeostasis 
[64–69]
Neurotrophins
[71–73]
Inflammation
[74]
Ca2+ homeostasis 
[6]
Dopamine 
homeostasis
[89]
Antioxidative 
properties
[91]
Ca2+ homeostasis
[92]
Immunomodulatory effects
[113]
Ca2+ homeostasis [114]
Reduced 
oligomerization of 
prions
[128]
Inflammation [141]
Ca2+ homeostasis 
[142]
Potential transcriptional 
regulation of HTT gene
[150]
Intervention studies Beneficial
[58]
Beneficial in 
dependence of 
genotype
[87]
Beneficial
[115–118]
Vit. D as genetic and 
environmental risk factor
[124]
/ Variable outcomes
[131, 134]
/
Vit. D, vitamin D; APP, amyloid precursor protein; Ca2+, calcium; PD, Parkinson’s disease; VDR, vitamin D receptor; ↓ reduced.
Table 1. 
Summary of the current research findings about the influence of vitamin D on selected neurodegenerative diseases Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, prion disease, 
amyotrophic lateral sclerosis, and Huntington’s disease in respect to epidemiological and clinical, animal and cell culture studies, identified molecular mechanisms, and intervention studies.
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diseases and reduced Vitamin D level; however, it has to be emphasized that many 
aspects of vitamin D remain obscure in these diseases. Therefore, further studies 
to clarify and judge a potential beneficial effect of vitamin D3 are needed to unravel 
the exact role of vitamin D in brain metabolism and neurodegenerative diseases. 
Especially determination of the individual serum 25(OH)D3 levels by appropriate 
methods like mass spectrometry and taking the individual patient’s competence to 
metabolize or form active vitamin D3 into consideration will help to avoid ambigu-
ous results. The fact that several prospective studies investigate a mixture of several 
different nutritional components makes it hard to trace the observed effects back to 
vitamin D in particular at the moment.
Interestingly some European countries, like Finland, already supplement 
vitamin D in general in food to prevent hypovitaminosis in the elderly population, 
and an optimal intake of 2000–4000 IU vitamin D or 10–20 min sunlight exposure 
per day is already recommended by experts, for example, at the Joint International 
Symposium Vitamin D in Prevention and Therapy and Biologic Effects of 
Light (2019). Further studies will help to validate the beneficial effects of these 
recommendations.
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